Swiss drugmaker Novartis is pressuring hospitals to stop making homebrew copies of its life-extending radiation therapies for cancer patients, but doctors say their drugs are safe and that the pharmaceutical giant is pricing outpatients by charging as much as $80,000 for a standard treatment.

Australia’s Telix Pharmaceuticals, which makes a diagnostic drug used alongside Novartis’ treatment for prostate cancer, is also on the warpath about copycats being made in local laboratories for a fraction of the price they charge for their proprietary medicines.